Related Experiment Video
Updated: Jan 14, 2026

Author Spotlight: Traditional Chinese Medicine for Sleep Disorders in Acute COPD — A Safe, Cost-Effective Approach
Published on: October 18, 2024
The impact of GLP-1 agonists on sleep disorders: spotlight on sleep apnea
Caroline S Mifsrud1, Bhanu Prakash Kolla2,3, David R Rushlow1
1Department of Family Medicine, Mayo Clinic, Rochester, MN, USA.
Introduction:
For the first time in history, a medication - tirzepatide, has been approved by the United States Food and Drug Administration (FDA) for the treatment of obstructive sleep apnea (OSA). This approval adds to the current array of therapeutic options and raises many issues regarding the future of treatment for OSA; in particular, the role of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in the chronic management of patients with OSA.
Areas Covered:
This review aims to summarize the impact of GLP-1 RAs for the treatment of OSA in the context of the recent FDA approval of tirzepatide following the SURMOUNT-OSA trial.
Expert Opinion:
The FDA approval of tirzepatide for OSA represents a major shift from symptom-based management with continuous positive airway pressure (CPAP) toward a weight-centered, disease-modifying strategy. Questions remain about whether benefits from GLP-1 RAs are purely weight-mediated, or whether they involve direct respiratory effects as well. Moving forward, pharmacotherapy could transform OSA management into a more individualized framework which views the condition as a chronic metabolic disease rather than solely a mechanical airway disorder.
Related Concept Videos
Sleep Apnea
The condition is more prevalent among...
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Management of Insomnia
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Dipeptidyl Peptidase 4 Inhibitors
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...

